Share
Carlos Martin
Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, has appointed Carlos Martin as Chief Commercial Officer (CCO).
Bringing more than 20 years of global biopharmaceutical leadership, Martin has an established track record in building high-performing commercial organizations, launching breakthrough therapies, and elevating pipeline value across innovative fields, including gene therapy, radiopharma, oncology, cardiology, and rare diseases.
Most recently, Martin served as CCO at Rocket Pharmaceuticals, where he led the company’s transformation from a clinical-stage biotech to a commercial-ready leader in gene therapy. During his tenure, he developed comprehensive commercialization strategies across the U.S., Europe, and Japan, designed go-to-market models, established commercial infrastructure, and secured key pre-launch payer agreements. His work accelerated Rocket’s readiness for market introduction while strengthening investor confidence and long-term enterprise value.
Earlier in his career, Martin held senior commercial leadership positions at Novartis Pharmaceuticals. At Advanced Accelerator Applications, a Novartis company, he built and led the U.S. radiopharma commercial business. At Novartis Oncology, he managed a $1B portfolio in the U.S. market and later served as Oncology Country Head in Chile, where he successfully established a new business unit.
Neurvati’s platform is built to advance clinically validated neuroscience programs with strong patient and market potential. The creation of the CCO role underscores the company’s commitment to embedding commercial strategy early, ensuring that promising therapies deliver meaningful value to patients, healthcare professionals, payors, and health systems. With Martin’s appointment, Neurvati strengthens its mission to translate rigorous science into impactful neuroscience breakthroughs worldwide.
